Gland Pharma Limited received tentative approval from the United States Food and Drug Administration (US FDA) for Angiotensin II for Injection, 2.5 mg/mL Single-Dose Vial. Gland Pharma received tentative approval from the United United States Food and Drug Administration ("US FDA") for Angiotensin II Injection, 2.5mg/mL Single Dose Vial. Gland Pharmaceutical Limited, a generic injectable focused pharmaceutical company, received tentative approval from the United US Food and Drug Administration (US FDA) for Angiotens in II Injection, 2. 5 mg/mL Single Dose Vials.

Gland Pharma believes that the only company with first to file for this product and may be eligible for 180 days of generic drug exclusivity. Gland Pharma will launch the product with its marketing partner on receipt of final approval. The Angiotensin II In injection, 2.5 mg/mL Single Dose Vial has US sales of approximately USD 38 million for twelve months ending in September 2023, according to IQVIA.